Germany / Highest Honours for BioNTech Founders; Bayer’s Growth Predictions; Merck Making Further French Investments
A roundup of some of the most important recent news from German pharma, including state honours for the founders of…
ProStrakan
Last updated: 13.02.2014
Address: ProStrakan Pharma GmbH
Monschauer Str. 1,
D-40549
Dusseldorf
Germany
Tel: +49 (0) 211/416 119-0
Web: http://www.prostrakan.com/
Company description
ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. With more than 300 people employed by the Company, ProStrakan is headquartered in Scotland with commercial operations throughout the rest of the UK and continental Europe and a US head office. The Company’s Development group is located in Galashiels, Scotland and Bedminster, New Jersey, US.ProStrakan has been listed on the main London Stock Exchange since 2005.
Products and services
Related
Germany / STADA’s Bold Bets on M&A
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness…
Germany / The Biotech Behind Pfizer’s COVID-19 Vaccine Candidate
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant…
Pharma Faces / Teresa Rodó, Head of Global Healthcare Operations, Merck
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to…
Merck KGaA / Big-Ticket Investments in Manufacturing Scale & Digital Innovation
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number…
Europe / A New Approach to Health Crises in France & Germany
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
News Roundup / German Pharma: February 2020
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big…
Bayer: Betting Big on Cell & Gene Therapy
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as…
Merck Announces EUR 1 Billion HQ Investment
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up…
Interview with Elmar Schnee , President of Merck Serono and Member of the…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout…
Interview with Andreas Fibig, CEO, Bayer Schering Pharma
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth…
Interview with Ralf Göddertz, General Manager of Germany, Austria and…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with…
